Compositions of buprenorphine and μ antagonists
The invention relates to a composition comprising buprenorphine and a μ opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ( BUP ) / EC 50 ] [ C max ( ANTAGONIST ) / IC 50 ] .
1. A method of treating a depressive disorder comprising administering a composition comprising about 2 mg to about 25 mg of buprenorphine and a therapeutically effective amount of Compound-1 to a patient in need thereof, wherein Compound-1 has the structure:
and
wherein said depressive disorder is selected from major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression; premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder.
2. The method according to claim 1 , wherein said depressive disorder is major depressive disorder.
3. The method according to claim 1 , comprising about 1.0 to about 20 mg of Compound-1.
4. The method according to claim 1 , comprising about 1.0 to about 10 mg of Compound-1.
5. The method according to claim 1 , comprising about 1.0 to about 8 mg of Compound-1.
6. The method according to claim 1 , comprising about 1.0 to about 4 mg of Compound-1.
7. The method according to claim 1 , comprising about 2 mg of Compound-1.
8. The method according to claim 1 , comprising about 2 mg to about 8 mg of buprenorphine.
9. The method according to claim 1 , comprising about 2 mg to about 4 mg of buprenorphine.
10. The method according to claim 1 , comprising about 2 mg of buprenorphine.
11. A method of treating a depressive disorder comprising administering a composition comprising about 0.5 mg to about 20 mg of Compound-1 and a therapeutically effective amount of buprenorphine to a patient in need thereof, wherein Compound-1 has the structure:
and
wherein said depressive disorder is selected from major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression; premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder.
12. The method according to claim 11 , wherein said depressive disorder is major depressive disorder.
13. The method according to claim 11 , comprising about 1.0 to about 10 mg of Compound-1.
14. The method according to claim 11 , comprising about 1.0 to about 8 mg of Compound-1.
15. The method according to claim 11 , comprising about 1.0 to about 4 mg of Compound-1.
16. The method according to claim 11 , comprising about 2 mg of Compound-1.
17. The method according to claim 11 , comprising about 2 mg to about 50 mg of buprenorphine.
18. The method according to claim 11 , comprising about 2 mg to about 8 mg of buprenorphine.
19. The method according to claim 11 , comprising about 2 mg to about 4 mg of buprenorphine.
20. The method according to claim 11 , comprising about 2 mg of buprenorphine.